What happened with CELC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Celcuity is a clinical-stage biotechnology company whose business centers on gedatolisib, a targeted therapy being tested for advanced breast cancer and prostate cancer. It has not commercialized a drug or generated revenue, and funds its work primarily through equity sales and borrowing.
Celcuity licenses exclusive worldwide rights to gedatolisib from Pfizer. If the drug receives regulatory approval, Celcuity plans to sell it; future sales would depend partly on government health programs and private insurers covering treatment and providing adequate reimbursement. Celcuity must pay Pfizer development and commercial milestone payments and royalties on drug sales, and maintaining the license requires it to meet its contractual obligations.
The business depends on completing clinical development and obtaining approval for gedatolisib. Celcuity relies on outside companies to manufacture and distribute the drug, including one primary manufacturer of its active ingredient. Approval would determine which uses it could promote, and the company would still need to build or arrange the capabilities to market and sell the drug.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Celcuity’s prospects hinge on gedatolisib’s approval and adoption in advanced breast cancer, where Roche’s Itovebi is an important competitor missing from this list.
Relay Therapeutics is developing zovegalisib for the same HR-positive, HER2-negative advanced breast-cancer market Celcuity targets with gedatolisib. Its drug inhibits PI3Kα, making that development program a direct competitor to watch.
AstraZeneca’s Truqap competes with Celcuity’s gedatolisib for HR-positive, HER2-negative advanced breast-cancer treatment. Truqap inhibits AKT, so it is a competing treatment to watch in the market Celcuity seeks to enter.
Novartis already sells Piqray and Afinitor in the advanced breast-cancer market Celcuity targets with gedatolisib. Both target components of the same signaling pathway, giving investors existing competing medicines to watch.
Celcuity depends on Pfizer’s permission to use essential gedatolisib patents and know-how under its license. Pfizer also sells Ibrance in the HR-positive breast-cancer treatment market Celcuity seeks to enter, making it both a licensing partner and a competitor.
Eli Lilly sells Verzenio for HR-positive, HER2-negative breast cancer, putting it in the treatment market Celcuity targets with gedatolisib regimens. Verzenio is the product to watch for this overlap, rather than Lilly’s broader medicine business.
Novartis AG earningsNVS
Novartis's report will show how Piqray and Afinitor are selling in advanced breast cancer, giving Celcuity a read on the commercial competition for gedatolisib.
Look for sales or demand information Novartis reports for Piqray and Afinitor. Strength would show that established pathway-targeting drugs retain a commercial foothold, so gedatolisib would need to persuade doctors and patients to switch if approved. Weakness would point to limited momentum for those products, not prove patients would choose an unapproved gedatolisib.
Eli Lilly & Co. earningsLLY
Lilly's report will show demand for Verzenio in HR-positive, HER2-negative breast cancer, giving Celcuity a read on use of an established treatment in its target market.
Look for Lilly's reported sales or demand for Verzenio. Strength would show that an established treatment continues to attract patients and doctors, making adoption harder for gedatolisib if approved. Weakness would suggest less momentum for Verzenio, but would not show that patients would switch to unapproved gedatolisib.
AstraZeneca PLC earningsAZN
AstraZeneca's report will show demand for Truqap in advanced breast cancer, revealing how another targeted treatment is competing in the market Celcuity seeks to enter.
Look for AstraZeneca's reported sales or demand for Truqap. Strength would show that an AKT-targeting treatment is attracting patients and doctors, making it harder for gedatolisib to win use if approved. Weakness would point to limited commercial demand for this competing therapy, not imply that demand transfers to unapproved gedatolisib.
Pfizer Inc. earningsPFE
Pfizer's report will show demand for Ibrance in breast cancer, a market where it competes with Celcuity, while Pfizer also licenses gedatolisib to the company.
Look for Pfizer's reported sales or demand for Ibrance. Strength would show it continues to win breast-cancer treatment use, leaving gedatolisib with a stronger competitor if approved; weakness would point to limited commercial momentum for Ibrance. Pfizer's role as licensor does not mean this report will reveal any change to the license or patent arrangements.
Celcuity Inc. earningsThis company
Celcuity has no product sales yet, and its report will show how quickly development and launch preparations for gedatolisib are using its cash.
Read cash used in operations alongside research and development and selling and administrative expenses. Slower cash use while trials and launch preparations continue would suggest spending is more controlled. Faster cash use with those expenses rising would put available funds and arranged financing under pressure sooner, making the company's expectation that funding lasts through 2027 harder to rely on.
